Program Description
The expanding
landscape of bispecific antibodies (BsAbs) has altered treatment decisions and
selection in the management of relapsed/refractory B-cell lymphomas. BsAbs
offer an "off-the-shelf" alternative to CAR T-cell therapy,
necessitating an in-depth understanding of updated treatment algorithms where
BsAbs are increasingly being integrated into the third-line setting and
investigated for earlier interventions. Oncology pharmacists are now at the
forefront of this transition, navigating complex sequencing decisions and
addressing real-world operational barriers as administration moves from
specialized academic centers into community oncology practices. Key operational
considerations include the development of institutional protocols for step-up
dosing and managing unique toxicities like cytokine release syndrome (CRS) and
ICANS, as well as the implementation of electronic health record (EHR) builds,
REMS compliance, and standardized compounding workflows. This session will
explore the clinical evidence for FDA-approved BsAbs, emerging combination
therapies, and multidisciplinary strategies for toxicity grading and patient
counseling. To facilitate the practical application of these concepts, the
program utilizes interactive, real-world patient cases and faculty-led
discussions to help attendees manage challenging scenarios encountered in daily
pharmacy practice.
Target audience: Oncology pharmacists
Type of activity: Application
Release date: May 12, 2026
Expiration date: May 12, 2027
Learner level: Foundational, Intermediate
Time to complete activity: .75 hour
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Group current bispecific antibodies (BsAbs) and evolving sequencing pathways into clinical practice for relapsed/refractory lymphoma management, enabling efficient BsAbs operationalization and improved access in community settings
- Construct multidisciplinary approaches to adverse effect recognition, prophylaxis, and management strategies in community settings, ensuring that community oncology pharmacists play a central role in patient education, toxicity grading, and continuity of care
- Apply the best practices for community pharmacist-led interventions, including order set builds, compounding/verification, infusion workflows, and electronic health record integration to reduce error risk and ensure patient safety
C. Brooke Adams, PharmD, BCOP
Clinical Pharmacy Specialist; Malignant Hematology, Stem Cell Transplant, and Cellular Therapy
PGY-2 Oncology Residency Program Coordinator
Orlando Health Cancer Institute
Orlando, FL
Brooke Peters, PharmD, BCOP
Clinical Pharmacist
American Oncology Network, LLC
Fort Myers, FL
Yonaton Resnick, PharmD
Vice President of Pharmacy
New England Cancer Specialists
Westbrook, ME
Accreditation
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.75 contact hours (0.075 CEU) under the ACPE universal activity number 0290-0000-26-112-H05-P. The activity is available for CE credit through May 12, 2027.
Instructions for Completing the Activity and Receiving CPE Credit
To receive CPE credit, participants must complete the pretest, view the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.
Faculty
The following contributors have no relevant financial relationships with ineligible companies to disclose:
Brooke Peters, PharmD, BCOP
Yonatan Resnick, PharmD
Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Rose Buszka, PharmD, BCPS, CHCP, Daphne Davis, PharmD, BCOP; Emily Tyler; Susan Pordon; Brianna Winters; and Chloe Taccetta have no relevant financial relationships with ineligible companies to disclose.
C. Brooke Adams, PharmD, BCOP has the following relevant financial relationships with ineligible companies to disclose: Consultant: Amgen, Bristol Myers Squibb, Incyte, Johnson & Johnson, Syndax; Speakers Bureau: AbbVie, Amgen, Genmab, GSK, Incyte, Johnson & Johnson, Omeros, Pfizer, Regeneron; Advisory Board: Amgen, Genmab, GSK, Incyte, Johnson & Johnson
Any relevant financial relationships listed for these individuals have been mitigated.
At least one anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with ineligible companies to disclose.
Educational Disclaimer
Continuing professional education activities are offered solely for educational
purposes and do not constitute any form of professional advice or referral.
Discussions concerning drugs, dosages, and procedures may reflect the clinical
experience of the author(s) or be derived from the professional literature or
other sources and may suggest uses that are investigational in nature and not
approved by the labeling or indications. Participants are encouraged to refer
to primary references or full prescribing information resources.
For questions about this internet CPE activity, please contact:
Privacy Policy and Terms of Use Information:
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here